Regec A L, Trump B F, Trifillis A L
Department of Pathology, University of Maryland School of Medicine, Baltimore 21201.
Biochem Pharmacol. 1989 Aug 1;38(15):2527-34. doi: 10.1016/0006-2952(89)90098-1.
Gentamicin treatment results in significant changes in lysosomal morphology and enzyme activity in renal tubular epithelium both in vivo and in vitro. In this study, cultured human proximal tubular cells (PTC) were treated with gentamicin (0, 0.01, 0.1, and 1.0 mg/ml) for 3, 7, 10 and 14 days, and the endocytotic activity, pH, and membrane fragility of the lysosomal system were examined. Fluorescein isothiocyanate-labeled dextran (FITC-dextran) was used to estimate endocytotic activity and intralysosomal pH. The fragility of isolated lysosomes was estimated by the release of N-acetyl-beta-glucosaminidase (NAG, EC3.2.1.30) into the medium. Gentamicin content was measured and correlated with the changes seen in lysosomal function. Gentamicin treatment caused a slight decrease in the rate with which human PTC accumulated FITC-dextran and a slight increase in intralysosomal pH. Treatment of human PTC with NH4Cl, a lysosomotropic compound, significantly increased the lysosomal pH; the NH4Cl-induced increase in the lysosomal pH of gentamicin-treated PTC, however, was not significantly different from control (0 mg gentamicin/ml). Lysosomes isolated from human PTC cultures released NAG upon incubation for 60 min at 37 degrees. There was no significant effect on the fragility of lysosomes isolated from cultures exposed to gentamicin for less than or equal to 7 days. Significantly increased fragility was seen, however, after 10 days of treatment with 1.0 mg gentamicin/ml and especially after a 14-day exposure to 0.01, 0.1, and 1.0 mg gentamicin/ml. Human PTC accumulated 0.47, 2.05 and 10.30 micrograms gentamicin/mg protein with 10 days of exposure to 0.01, 0.1 and 1.0 mg gentamicin/ml medium respectively. Gentamicin treatment associated with increased numbers of morphologically altered lysosomes, i.e. myeloid bodies, did not affect significantly the endocytotic activity and pH of lysosomes in cultured human PTC. Prolonged exposure (14 days) of human PTC to gentamicin, however, did increase the fragility of lysosomes after isolation. The increased numbers of morphologically altered lysosomes with increased fragility were not associated with any significant in vitro cell death. Therefore, it would appear that these lysosomal alterations are not directly responsible for the in vivo nephrotoxicity.
庆大霉素治疗在体内和体外均可导致肾小管上皮细胞溶酶体形态和酶活性发生显著变化。在本研究中,将培养的人近端肾小管细胞(PTC)用庆大霉素(0、0.01、0.1和1.0mg/ml)处理3、7、10和14天,然后检测溶酶体系统的内吞活性、pH值和膜脆性。用异硫氰酸荧光素标记的葡聚糖(FITC-葡聚糖)来评估内吞活性和溶酶体内pH值。通过N-乙酰-β-氨基葡萄糖苷酶(NAG,EC3.2.1.30)释放到培养基中来评估分离的溶酶体的脆性。测定庆大霉素含量,并将其与溶酶体功能的变化相关联。庆大霉素处理导致人PTC积累FITC-葡聚糖的速率略有下降,溶酶体内pH值略有升高。用溶酶体促渗剂氯化铵处理人PTC可显著提高溶酶体pH值;然而,氯化铵诱导的庆大霉素处理的PTC溶酶体pH值升高与对照(0mg庆大霉素/ml)无显著差异。从人PTC培养物中分离的溶酶体在37℃孵育60分钟后释放NAG。暴露于庆大霉素小于或等于7天的培养物中分离的溶酶体的脆性没有显著影响。然而,在用1.0mg庆大霉素/ml处理10天后,尤其是在暴露于0.01、0.1和1.0mg庆大霉素/ml 14天后,观察到脆性显著增加。人PTC在分别暴露于0.01、0.1和1.0mg庆大霉素/ml培养基10天后,每毫克蛋白质积累0.47、2.05和10.30微克庆大霉素。庆大霉素处理导致形态改变的溶酶体(即髓样小体)数量增加,但对培养的人PTC中溶酶体的内吞活性和pH值没有显著影响。然而,人PTC长时间(14天)暴露于庆大霉素确实会增加分离后溶酶体的脆性。形态改变的溶酶体数量增加且脆性增加与任何显著的体外细胞死亡无关。因此,似乎这些溶酶体改变并非体内肾毒性的直接原因。